Penserra Capital Management LLC Sells 16,224 Shares of Natera, Inc. (NASDAQ:NTRA)

Penserra Capital Management LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 96.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 566 shares of the medical research company’s stock after selling 16,224 shares during the quarter. Penserra Capital Management LLC’s holdings in Natera were worth $80,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of NTRA. LRI Investments LLC purchased a new position in Natera during the 4th quarter valued at $29,000. Rakuten Securities Inc. lifted its holdings in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after buying an additional 119 shares during the period. ORG Partners LLC purchased a new stake in shares of Natera in the 1st quarter worth $32,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after buying an additional 261 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after buying an additional 332 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $160.43 on Friday. The business’s 50-day moving average is $161.05 and its 200 day moving average is $158.41. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm has a market capitalization of $21.91 billion, a P/E ratio of -109.14 and a beta of 1.73.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same period in the prior year, the company posted ($0.56) EPS. The firm’s quarterly revenue was up 36.5% compared to the same quarter last year. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen cut Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Barclays upped their target price on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. UBS Group upped their target price on Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Finally, Piper Sandler upped their target price on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $184.63.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.07, for a total value of $471,210.00. Following the transaction, the insider directly owned 133,205 shares of the company’s stock, valued at approximately $20,922,509.35. This represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares in the company, valued at $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,272 shares of company stock valued at $8,345,368. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.